{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:47:54Z","timestamp":1792676874320,"version":"4.5.0"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CanAg (CA242) is a carbohydrate antigen highly overexpressed in most gastrointestinal cancers, with minimal expression in normal tissue, making it an attractive target for antibody\u2013drug conjugate (ADC) therapeutics in these cancers. Previous efforts to target CanAg with ADCs have shown limited clinical efficacy, possibly due to resistance to the tubulin inhibitor payloads used. IKS04 is a novel CanAg-targeting ADC comprising an anti-CanAg humanized mAb Isumab04 and a highly potent pyrrolobenzodiazepine prodrug payload. However, the use of potent payloads such as pyrrolobenzodiazepines can limit the maximum tolerated dose of ADCs, which in turn limits tumor tissue penetration and efficacy, particularly for high-expression targets such as CanAg. Coadministration of unconjugated antibody can potentially improve tumor tissue penetration, resulting in increased ADC efficacy. In this study, we evaluated the impact of Isumab04 coadministration on the distribution and efficacy of IKS04 in human tumor xenograft mouse models with different CanAg expression levels. Although the addition of the Isumab04 antibody showed minimal impact on IKS04 cell\u2013killing activity in vitro in cells with moderate and high CanAg expression, coadministration of Isumab04 with IKS04 improved tumor tissue distribution of the ADC in both tumor spheroids and in vivo tumor models. This improved distribution correlated with increased efficacy in vivo, in which increasing doses of unconjugated antibody resulted in greater efficacy until apparent tumor saturation was reached. These results support the use of antibody coadministration to improve the efficacy of ADCs targeting high-expression antigens with highly potent payloads.<\/jats:p>","DOI":"10.1158\/1535-7163.mct-25-0484","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T07:58:03Z","timestamp":1759823883000},"page":"1845-1855","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["IKS04, a CanAg-Targeting Antibody\u2013Drug Conjugate with Pyrrolobenzodiazepine, Shows Enhanced Efficacy with Unconjugated Antibody Coadministration in Animal Models"],"prefix":"10.1158","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-7294","authenticated-orcid":false,"given":"Haolong","family":"Huang","sequence":"first","affiliation":[{"name":"1Chemical Engineering, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2770-3560","authenticated-orcid":false,"given":"Jutta","family":"Deckert","sequence":"additional","affiliation":[{"name":"2Iksuda Therapeutics, Newcastle upon Tyne, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8923-7945","authenticated-orcid":false,"given":"Justyna","family":"Mysliwy","sequence":"additional","affiliation":[{"name":"2Iksuda Therapeutics, Newcastle upon Tyne, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4662-8936","authenticated-orcid":false,"given":"Adam","family":"Lodge","sequence":"additional","affiliation":[{"name":"2Iksuda Therapeutics, Newcastle upon Tyne, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2896-3231","authenticated-orcid":false,"given":"Robert J.","family":"Lutz","sequence":"additional","affiliation":[{"name":"2Iksuda Therapeutics, Newcastle upon Tyne, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-2080","authenticated-orcid":false,"given":"Greg M.","family":"Thurber","sequence":"additional","affiliation":[{"name":"1Chemical Engineering, University of Michigan, Ann Arbor, Michigan."},{"name":"3Biomedical Engineering, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2025120203092834300_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2003.05.137","article-title":"Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study","volume":"21","author":"Tolcher","year":"2003","journal-title":"J Clin Oncol"},{"key":"2025120203092834300_bib2","doi-asserted-by":"crossref","first-page":"21537","DOI":"10.1016\/S0021-9258(18)54672-X","article-title":"Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins","volume":"266","author":"Baeckstr\u00f6m","year":"1991","journal-title":"J Biol Chem"},{"key":"2025120203092834300_bib3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/bjc.1989.377","article-title":"Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9","volume":"60","author":"Haglund","year":"1989","journal-title":"Br J Cancer"},{"key":"2025120203092834300_bib4","doi-asserted-by":"crossref","first-page":"8618","DOI":"10.1073\/pnas.93.16.8618","article-title":"Eradication of large colon tumor xenografts by targeted delivery of maytansinoids","volume":"93","author":"Liu","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025120203092834300_bib5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00280-007-0672-8","article-title":"Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study","volume":"62","author":"Rodon","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025120203092834300_bib6","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1158\/1078-0432.CCR-04-0088","article-title":"A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors","volume":"10","author":"Helft","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2025120203092834300_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.31083\/j.fbl2711301","article-title":"Antibody-drug conjugates targeting tumor-specific mucin glycoepitopes","volume":"27","author":"Brassard","year":"2022","journal-title":"Front Bioscience-Landmark"},{"key":"2025120203092834300_bib8","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1021\/jm060319f","article-title":"Semisynthetic maytansine analogues for the targeted treatment of cancer","volume":"49","author":"Widdison","year":"2006","journal-title":"J Med Chem"},{"issue":"suppl","key":"2025120203092834300_bib9","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/jco.2007.25.18_suppl.3062","article-title":"A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors","volume":"25","author":"Mita","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025120203092834300_bib10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6605229","article-title":"Slow proliferation as a biological feature of colorectal cancer metastasis","volume":"101","author":"Anjomshoaa","year":"2009","journal-title":"Br J Cancer"},{"key":"2025120203092834300_bib11","first-page":"2328","article-title":"Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells","volume":"41","author":"Drewinko","year":"1981","journal-title":"Cancer Res"},{"key":"2025120203092834300_bib12","first-page":"3152","article-title":"Cell cycle phase-specific cytotoxicity of the antitumor agent maytansine","volume":"39","author":"Rao","year":"1979","journal-title":"Cancer Res"},{"key":"2025120203092834300_bib13","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/0008-5472.CAN-05-3973","article-title":"Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen","volume":"66","author":"Kovtun","year":"2006","journal-title":"Cancer Res"},{"key":"2025120203092834300_bib14","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s10637-011-9647-z","article-title":"DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c] [1,4]benzodiazepine dimer SG2057","volume":"30","author":"Hartley","year":"2012","journal-title":"Investig New Drugs"},{"key":"2025120203092834300_bib15","first-page":"54","volume-title":"Advances in the study of Pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) antitumour antibiotics","author":"Thurston","year":"1993"},{"key":"2025120203092834300_bib16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1021\/tx00005a002","article-title":"Pyrrolo [1, 4] benzodiazepine antitumor antibiotics: relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds","volume":"1","author":"Hurley","year":"1988","journal-title":"Chem Res Toxicol"},{"key":"2025120203092834300_bib17","doi-asserted-by":"crossref","first-page":"13756","DOI":"10.1021\/ja902986x","article-title":"The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links","volume":"131","author":"Rahman","year":"2009","journal-title":"J Am Chem Soc"},{"key":"2025120203092834300_bib18","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1158\/0008-5472.CAN-03-2941","article-title":"SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity","volume":"64","author":"Hartley","year":"2004","journal-title":"Cancer Res"},{"key":"2025120203092834300_bib19","doi-asserted-by":"crossref","first-page":"8232","DOI":"10.1021\/bi034313t","article-title":"Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers","volume":"42","author":"Smellie","year":"2003","journal-title":"Biochemistry"},{"key":"2025120203092834300_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/bjc.1994.248","article-title":"Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents","volume":"70","author":"Smellie","year":"1994","journal-title":"Br J Cancer"},{"key":"2025120203092834300_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ddtec.2018.10.004","article-title":"Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: is mechanism related to systemic toxicity?","volume":"30","author":"Jackson","year":"2018","journal-title":"Drug Discov Today Tech"},{"key":"2025120203092834300_bib22","doi-asserted-by":"crossref","first-page":"104429","DOI":"10.1016\/j.yrtph.2019.104429","article-title":"An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates","volume":"107","author":"Saber","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"key":"2025120203092834300_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ejmech.2019.06.044","article-title":"Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual \u03b2-glucuronide and dipeptide triggers","volume":"179","author":"Gregson","year":"2019","journal-title":"Eur J Med Chem"},{"key":"2025120203092834300_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.106.2742.66","article-title":"Comparison of the \u03b2-glucuronidase activity of normal, tumor, and lymph node tissues of surgical patients","volume":"106","author":"Fishman","year":"1947","journal-title":"Science"},{"key":"2025120203092834300_bib25","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2174\/1381612023394485","article-title":"Beta-glucuronidase-mediated drug release","volume":"8","author":"de Graaf","year":"2002","journal-title":"Curr Pharm Des"},{"key":"2025120203092834300_bib26","doi-asserted-by":"crossref","first-page":"2102414","DOI":"10.1002\/advs.202102414","article-title":"An elaborate new linker system significantly enhances the efficacy of an HER2-antibody-drug conjugate against refractory HER2-positive cancers","volume":"8","author":"Shin","year":"2021","journal-title":"Adv Sci"},{"key":"2025120203092834300_bib27","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1038\/s41467-024-48798-w","article-title":"HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a\/1b trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"2025120203092834300_bib28","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1016\/j.bmcl.2008.05.038","article-title":"Pyrrolo[2,1-c] [1,4]benzodiazepine-\u03b2-glucuronide prodrugs with a potential for selective therapy of solid tumors by PMT and ADEPT strategies","volume":"18","author":"Kamal","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"2025120203092834300_bib29","doi-asserted-by":"crossref","first-page":"eadk1894","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"Rubahamya","year":"2024","journal-title":"Sci Adv"},{"key":"2025120203092834300_bib30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1208\/s12248-016-9940-z","article-title":"Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy","volume":"18","author":"Cilliers","year":"2016","journal-title":"AAPS J"},{"key":"2025120203092834300_bib31","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/0008-5472.CAN-17-1638","article-title":"Improved tumor penetration and single-cell targeting of antibody\u2013drug conjugates increases anticancer efficacy and host survival","volume":"78","author":"Cilliers","year":"2018","journal-title":"Cancer Res"},{"key":"2025120203092834300_bib32","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2967\/jnumed.106.037069","article-title":"Theoretic criteria for antibody penetration into solid tumors and micrometastases","volume":"48","author":"Thurber","year":"2007","journal-title":"J Nucl Med"},{"key":"2025120203092834300_bib33","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00262-008-0518-1","article-title":"Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability","volume":"57","author":"Schmidt","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"2025120203092834300_bib34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1535-7163.MCT-21-0580","article-title":"Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates","volume":"21","author":"Khera","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2025120203092834300_bib35","first-page":"57","article-title":"Factors determining antibody distribution in tumors","volume":"29","author":"Thurber","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"2025120203092834300_bib36","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s11307-015-0851-7","article-title":"Residualization rates of near-infrared dyes for the rational design of molecular imaging agents","volume":"17","author":"Cilliers","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"2025120203092834300_bib37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11307-010-0397-7","article-title":"Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels","volume":"13","author":"Thurber","year":"2011","journal-title":"Mol Imaging Biol"},{"key":"2025120203092834300_bib38","first-page":"13","article-title":"Predictive simulations in preclinical oncology to guide the translation of biologics","volume":"13","author":"Dong","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025120203092834300_bib39","volume-title":"Distribution and Metabolism of Antibodies and Macromolecules in Tumor Tissue","author":"Thurber","year":"2008"},{"key":"2025120203092834300_bib40","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s11095-024-03715-0","article-title":"Optimizing solid tumor treatment with antibody\u2013drug conjugates using agent-based modeling: considering the role of a carrier dose and payload class","volume":"41","author":"Calopiz","year":"2024","journal-title":"Pharm Res"},{"key":"2025120203092834300_bib41","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","article-title":"Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing","volume":"66","author":"Erickson","year":"2006","journal-title":"Cancer Res"},{"key":"2025120203092834300_bib42","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1124\/jpet.103.060533","article-title":"Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice","volume":"308","author":"Xie","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"suppl","key":"2025120203092834300_bib43","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2024.42.16_suppl.3023","article-title":"A phase 1a\/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas","volume":"42","author":"Lemech","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025120203092834300_bib44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1208\/s12248-019-0387-x","article-title":"Antibody coadministration as a strategy to overcome binding-site barrier for ADCs: a quantitative investigation","volume":"22","author":"Singh","year":"2020","journal-title":"AAPS J"},{"key":"2025120203092834300_bib45","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2025120203092834300_bib46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.semnuclmed.2009.11.002","article-title":"Radioimmunotherapy of lymphoma: bexxar and zevalin","volume":"40","author":"Goldsmith","year":"2010","journal-title":"Semin Nucl Med"},{"key":"2025120203092834300_bib47","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Molecular Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/doi\/10.1158\/1535-7163.MCT-25-0484\/3658707\/mct-25-0484.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/doi\/10.1158\/1535-7163.MCT-25-0484\/3664957\/mct-25-0484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/24\/12\/1845\/3683949\/mct-25-0484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/24\/12\/1845\/3683949\/mct-25-0484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:09:43Z","timestamp":1764662983000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mct\/article\/24\/12\/1845\/768315\/IKS04-a-CanAg-Targeting-Antibody-Drug-Conjugate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,7]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1158\/1535-7163.mct-25-0484","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1535-7163.30761579","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.30761591","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.30761570","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.30761588","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.30761567","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.30761564","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.30761576","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.30761573","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.30761585","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.30761582","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.30761594","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1535-7163.c.8179127","asserted-by":"object"}]},"ISSN":["1535-7163","1538-8514"],"issn-type":[{"value":"1535-7163","type":"print"},{"value":"1538-8514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]}}}